FDA Removes Clinical Hold from Aastrom Phase II IMPACT-DCM Clinical Trial

News   Jun 23, 2009

 
FDA Removes Clinical Hold from Aastrom Phase II IMPACT-DCM Clinical Trial
 
 
 

RELATED ARTICLES

Concept Life Sciences appoints New Group Programme Manager and US Head of Sales

News

Key leadership appointments support integration of the Group and expansion in the US market.

READ MORE

Brian Berridge Set to Manage National Toxicology Program

News

The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.

READ MORE

Heart-muscle Patches Created from Human Cells Improve Recovery from Heart Attacks

News

Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery from heart attack injury.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE